nivolumab,ipilimumab
BMS
['breast']
from #esmo22: patients with triple-negative breast cancer may be more likely to respond to immune checkpoint inhibitor therapy if they have higher concentrations of tumor-infiltrating lymphocytes. 
https://t.co/bi63MIVP5D is a resource offering oncology health care professionals practical information about the changing clinical landscape.